Quigley Corp. officially appoints interim CEO Karkus to post

DOYLESTOWN, Pa. Quigley Corp. on Friday named Ted Karkus, chairman, the company’s CEO.

Robert Cuddihy has been appointed COO.

Karkus recently conducted a successful proxy contest which resulted in his slate of directors being elected to the board last month. He had been serving as interim CEO since June 12.

Karkus has 25 years of Wall Street experience and since 1996 has been providing management consulting services to emerging-growth companies. Karkus assisted the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline for more than $1.4 billion.

Cuddihy has more than 20 years of experience as the COO and/or CFO of two public companies — HMG Worldwide Corporation, which focused on retail, planning and merchandising; and iDNA Inc., which focused on corporate communications.  Most recently, Cuddihy served as the president of Shannon Hill Associates.

Former chairman, president and CEO Guy Quigley announced his resignation last month, following a contentious proxy contest which culminated on May 20 at the company’s annual meeting and favored shareholder Karkus and his proposed slate of directors.

Quigley Co. also accepted the resignation of Charles Phillips, COO, and Wendy Quigley, accounting operations manager, last month.